What question did this study set out to answer?

This study aims to investigate the pharmacological effects of quinapril in lowering blood pressure in hypertensive and heart failure patients.

April 1, 1989Angiology

Clinical Pharmacology of Quinapril in Healthy Volunteers and in Patients with Hypertension and Congestive Heart Failure

View Full Paper

Ask AI

Bookmark

Why the study?

Does quinapril lower diastolic blood pressure in patients with hypertension and improve hemodynamics in congestive heart failure?

Key Points

This study aims to investigate the pharmacological effects of quinapril in lowering blood pressure in hypertensive and heart failure patients.
Conducted a double-blind, placebo-controlled trial of quinapril doses (5, 10, and 20 mg) administered once daily.
Included a 24-hour blood pressure monitoring study to assess effectiveness on diastolic blood pressure (DBP).
Performed initial dose-ranging studies in healthy volunteers to establish pharmacokinetics.
Quinapril 10 mg and 20 mg significantly lowered sitting DBP compared to placebo (p < 0.05).
5 mg of quinapril showed minimal clinical effectiveness in lowering DBP.
Patients may require twice-daily dosing to achieve sustained BP reductions over 24 hours.

Structured PICO

Does quinapril lower diastolic blood pressure in patients with hypertension and improve hemodynamics in congestive heart failure?

Population

Healthy volunteers, patients with mild to moderate hypertension, and patients with refractory congestive heart failure

Intervention

Quinapril (0.625 mg to 80 mg single doses; 5, 10, and 20 mg once or twice daily)

Comparator

Placebo

Outcome

Sitting diastolic blood pressure (DBP), plasma ACE activity, and hemodynamic effectssurrogate

Quinapril is an effective ACE inhibitor that significantly lowers diastolic blood pressure at doses of 10-20 mg daily and provides favorable hemodynamic effects in heart failure.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

May support quinapril 10-20 mg for DBP lowering; leaves open optimal dosing frequency and heart failure outcomes.

Cite This Study

Sedman et al. (1989) studied this question.

synapsesocial.com/papers/6a71467e31a3df8243297ae4 https://doi.org/10.1177/000331978904000405

Topics

Hypertension management HFrEF treatment Heart failure

View Full Paper

Ask AI

Bookmark

Clinical Pharmacology of Quinapril in Healthy Volunteers and in Patients with Hypertension and Congestive Heart Failure

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Topics

Clinical Pharmacology of Quinapril in Healthy Volunteers and in Patients with Hypertension and Congestive Heart Failure

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider